Stubborn Valeant powers ahead with extended Allergan buyout offer

Valeant's ($VRX) tender offer for Allergan ($AGN) isn't expiring just yet. The company has extended the deadline to Dec. 31, giving it and activist investor partner Bill Ackman a few more months to go after deal-averse Allergan. At least one supporter is betting heavily that the Canadian pharma can pull the deal off: Paulson & Co. acquired 5.6 million shares of Allergan valued at nearly $1 billion during the second quarter, Bloomberg reports. News (sub. req.) | More

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.